HUS1600058I1 - Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal - Google Patents

Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal

Info

Publication number: HUS1600058I1
Authority: HU; Hungary
Prior art keywords: nnrtis; pyrimidine; inhibitors; combinations; containing nnrtis
Prior art date: 2003-09-03

Application number

HUS1600058C

Other languages

English (en)

Original Assignee

Janssen Sciences Ireland Unlimited Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-03

Filing date

2016-12-20

Publication date

2017-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1600058(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-12-20 Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co

2017-02-28 Publication of HUS1600058I1 publication Critical patent/HUS1600058I1/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

HUS1600058C 2003-09-03 2016-12-20 Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal HUS1600058I1 (hu)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US49977103P	2003-09-03	2003-09-03
EP03103275		2003-09-03
EP03103319		2003-09-08
EP03103335		2003-09-10
EP03103668		2003-10-02
US50848603P	2003-10-03	2003-10-03
EP04787096.9A EP1663240B2 (en)	2003-09-03	2004-09-03	Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en)	2003-09-03	2004-09-03	Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (1)

Publication Number	Publication Date
HUS1600058I1 true HUS1600058I1 (hu)	2017-02-28

Family

ID=34280181

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
HUS1500053C HUS1500053I1 (hu)	2003-09-03	2015-10-21	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1500052C HUS1500052I1 (hu)	2003-09-03	2015-10-21	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1500054C HUS1500054I1 (hu)	2003-09-03	2015-10-21	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1600058C HUS1600058I1 (hu)	2003-09-03	2016-12-20	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1600059C HUS1600059I1 (hu)	2003-09-03	2016-12-20	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
HUS1500053C HUS1500053I1 (hu)	2003-09-03	2015-10-21	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1500052C HUS1500052I1 (hu)	2003-09-03	2015-10-21	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
HUS1500054C HUS1500054I1 (hu)	2003-09-03	2015-10-21	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUS1600059C HUS1600059I1 (hu)	2003-09-03	2016-12-20	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal

Country Status (24)

Country	Link
US (9)	US20080200435A1 (hu)
EP (1)	EP1663240B2 (hu)
JP (3)	JP5507791B2 (hu)
KR (1)	KR20060090658A (hu)
CN (1)	CN101060844B (hu)
AP (1)	AP2109A (hu)
AU (5)	AU2004268390B2 (hu)
BE (1)	BE2015C053I2 (hu)
CA (1)	CA2537095C (hu)
CY (5)	CY2015038I2 (hu)
FI (1)	FI1663240T4 (hu)
FR (5)	FR15C0072I2 (hu)
HR (1)	HRP20150798T4 (hu)
HU (5)	HUS1500053I1 (hu)
IL (2)	IL173438A (hu)
LT (2)	LTC1663240I2 (hu)
LU (3)	LU92853I2 (hu)
MX (1)	MXPA06002437A (hu)
MY (1)	MY169670A (hu)
NL (2)	NL300781I1 (hu)
NO (6)	NO334877B1 (hu)
NZ (1)	NZ545306A (hu)
PL (1)	PL1663240T5 (hu)
WO (1)	WO2005021001A1 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8101629B2 (en)	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2686429C (en)	2002-08-09	2010-11-16	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
EA201100293A1 (ru)	2003-01-14	2011-08-30	Джилид Сайэнс, Инк.	Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
WO2006024668A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
UA92469C2 (en) *	2004-09-02	2010-11-10	Янссен Фармацевтика Н.В.	Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
DK1632232T6 (da) *	2004-09-02	2022-04-19	Janssen Pharmaceutica Nv	Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
KR101276571B1 (ko) *	2004-09-02	2013-06-18	얀센 파마슈티카 엔.브이.	4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트
US20090215804A1 (en) *	2004-09-02	2009-08-27	Paul Theodoor Agnes Stevens	Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile
TWI457136B (zh) *	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
AP2008004533A0 (en) *	2005-12-14	2008-08-31	Cipla Ltd	Pharmaceutical combination
JP5754005B2 (ja) *	2006-01-20	2015-07-22	ヤンセン・アールアンドデイ・アイルランド	Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
US9044509B2 (en)	2006-02-03	2015-06-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr)	2006-07-05	2008-09-26	Univ Aix Marseille Ii	Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
EP2234620B1 (fr) *	2008-01-03	2016-03-09	Université d'Aix-Marseille	Tritherapie utilisable lors du traitement d'un patient infecte par le vih
ES2607107T3 (es) *	2008-12-24	2017-03-29	Janssen Sciences Ireland Uc	Dispositivos implantables para tratar el VIH
MX2012007210A (es)	2009-12-21	2012-07-23	Janssen R & D Ireland	Implante removible degradable para la liberacion sostenida de un compuesto activo.
SMT201800290T1 (it)	2010-01-27	2018-07-17	Viiv Healthcare Co	Terapia antivirale
AP3816A (en) *	2010-11-19	2016-09-30	Gilead Sciences Inc	Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
US9233935B2 (en) *	2011-09-16	2016-01-12	Hetero Research Foundation	Rilpivirine hydrochloride
PE20151499A1 (es)	2012-12-21	2015-10-29	Gilead Sciences Inc	Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
SI3346995T1 (sl)	2015-11-09	2019-11-29	Gilead Sciences Inc	Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
CN110191704A (zh)	2016-10-24	2019-08-30	爱尔兰詹森科学公司	可分散组合物
WO2018119371A1 (en) *	2016-12-23	2018-06-28	Temple University - Of The Commonwealth System Of Higher Education	Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
WO2018193470A1 (en) *	2017-04-18	2018-10-25	Cipla Limited	Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) *	2017-07-27	2019-01-31	Cipla Limited	PHARMACEUTICAL COMPOSITIONS
CA3152105A1 (en)	2019-11-29	2021-06-03	Wai Yip Thomas Lee	Composition including rilpivirine and use thereof for treating tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182111A (en) *	1987-11-17	1993-01-26	Boston University Research Foundation	In vivo delivery of active factors by co-cultured cell implants
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
US5368864A (en) *	1988-11-25	1994-11-29	Henning Berlin Gmbh Chemie- Und Pharmawerk	Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en)	1989-12-22	1994-04-30	The Wellcome Foundation Ltd	Therapeutic nucleosides.
ES2093106T3 (es)	1990-07-19	1996-12-16	Otsuka Pharma Co Ltd	Preparacion solida.
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
JPH07503943A (ja) *	1991-10-29	1995-04-27	クローバー　コンソリデイテッド，リミテッド	封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
WO1993023021A2 (en)	1992-05-13	1993-11-25	The Wellcome Foundation Limited	Therapeutic combinations
JPH06316524A (ja)	1992-09-11	1994-11-15	Naoyuki Inoue	抗エイズウイルス剤
TW401303B (en) *	1994-07-01	2000-08-11	Janssen Pharmaceutica Nv	Anti-HIV triple combination
IT1281502B1 (it) *	1995-06-13	1998-02-18	Sardinian Antiviral Research C	Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP1214059B1 (en)	1999-09-21	2005-05-25	Skyepharma Canada Inc.	Surface modified particulate compositions of biologically active substances
US6743446B2 (en) *	1999-12-15	2004-06-01	The Ohio State University Research Foundation	Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) *	2000-01-27	2007-07-21	Zentaris Ag	Compressed microparticles for dry injection
MXPA02009534A (es)	2000-03-30	2003-05-14	Squibb Bristol Myers Co	Granulos de liberacion sostenida que contienen estavudina.
US20040115268A1 (en) *	2000-04-26	2004-06-17	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
DE10050199A1 (de)	2000-10-11	2002-04-25	Ethicon Gmbh	Flächiges Implantat mit im Ultraschall detektierbaren Elementen
WO2002048141A1 (fr)	2000-12-11	2002-06-20	Takeda Chemical Industries, Ltd.	Composition medicinale dont la solubilite dans l'eau est amelioree
CA2450957A1 (en)	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
JO3429B1 (ar) †	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030166509A1 (en)	2001-11-20	2003-09-04	Advanced Inhalation Research, Inc.	Compositions for sustained action product delivery and methods of use thereof
CA2686429C (en)	2002-08-09	2010-11-16	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7497855B2 (en) *	2002-09-04	2009-03-03	Microchips, Inc.	Method and device for the controlled delivery of parathyroid hormone
AU2003291457A1 (en)	2002-11-08	2004-06-03	Glaxo Group Limited	Pharmaceutical antiviral compositions
NZ540321A (en)	2002-11-15	2007-09-28	Tibotec Pharm Ltd	Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (en)	2002-11-29	2004-06-17	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
NZ541902A (en)	2003-02-07	2008-12-24	Janssen Pharmaceutica Nv	Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (ko) *	2004-01-27	2006-09-28	씨제이 주식회사	결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
JP2008501802A (ja)	2004-06-08	2008-01-24	バーテックス　ファーマシューティカルズ　インコーポレイテッド	医薬組成物
MY191349A (en)	2004-08-27	2022-06-17	Bayer Pharmaceuticals Corp	New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DK1632232T6 (da)	2004-09-02	2022-04-19	Janssen Pharmaceutica Nv	Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril
WO2006024668A1 (en)	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
KR20130030305A (ko)	2004-11-16	2013-03-26	엘란 파마 인터내셔널 리미티드	주사가능한 나노입자형 올란자핀 제형
TWI457136B (zh)	2005-04-04	2014-10-21	Tibotec Pharm Ltd	Ｈｉｖ-感染之預防
AU2006235565A1 (en) *	2005-04-11	2006-10-19	The Board Of Trustees Of The Leland Stanford Junior University	Multi-layer structure having a predetermined layer pattern including an agent
TW200710091A (en)	2005-04-11	2007-03-16	Tibotec Pharm Ltd	(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20090142401A1 (en)	2005-06-07	2009-06-04	Leah Elizabeth Appel	Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
EP1912730A2 (en)	2005-07-28	2008-04-23	Isp Investments Inc.	Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
JP5754005B2 (ja)	2006-01-20	2015-07-22	ヤンセン・アールアンドデイ・アイルランド	Ｔｃｍ２７８を用いるｈｉｖ−感染症の長期間処置
AR061620A1 (es)	2006-06-23	2008-09-10	Tibotec Pharm Ltd	Suspensiones acuosas de tmc278
WO2008060360A2 (en) *	2006-09-28	2008-05-22	Surmodics, Inc.	Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
HRP20131128T1 (hr)	2007-07-12	2013-12-20	Janssen R&D Ireland	Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
US20090123508A1 (en)	2007-10-04	2009-05-14	Boston Scientific Scimed, Inc.	Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
US20110257111A1 (en) *	2008-10-24	2011-10-20	Harbeson Scott L	Hydroxyethlamino Sulfonamide Derivatives

2004
- 2004-09-02 MY MYPI20043578A patent/MY169670A/en unknown
- 2004-09-03 AU AU2004268390A patent/AU2004268390B2/en not_active Expired
- 2004-09-03 JP JP2006525150A patent/JP5507791B2/ja not_active Expired - Lifetime
- 2004-09-03 KR KR1020067003074A patent/KR20060090658A/ko not_active Ceased
- 2004-09-03 CN CN2004800254267A patent/CN101060844B/zh not_active Expired - Lifetime
- 2004-09-03 PL PL04787096.9T patent/PL1663240T5/pl unknown
- 2004-09-03 MX MXPA06002437A patent/MXPA06002437A/es active IP Right Grant
- 2004-09-03 CA CA2537095A patent/CA2537095C/en not_active Expired - Lifetime
- 2004-09-03 US US10/570,228 patent/US20080200435A1/en not_active Abandoned
- 2004-09-03 EP EP04787096.9A patent/EP1663240B2/en not_active Expired - Lifetime
- 2004-09-03 WO PCT/EP2004/052028 patent/WO2005021001A1/en not_active Ceased
- 2004-09-03 NZ NZ545306A patent/NZ545306A/en not_active IP Right Cessation
- 2004-09-03 AP AP2006003551A patent/AP2109A/en active
2006
- 2006-01-30 IL IL173438A patent/IL173438A/en active Protection Beyond IP Right Term
- 2006-03-27 NO NO20061374A patent/NO334877B1/no active Protection Beyond IP Right Term
2009
- 2009-10-07 US US12/574,881 patent/US8841310B2/en not_active Expired - Lifetime
2011
- 2011-03-14 AU AU2011201123A patent/AU2011201123B2/en not_active Expired
- 2011-05-24 IL IL213104A patent/IL213104A/en active IP Right Grant
- 2011-10-12 JP JP2011224982A patent/JP2012051915A/ja not_active Withdrawn
2014
- 2014-06-26 AU AU2014203484A patent/AU2014203484B2/en active Active
- 2014-08-07 US US14/454,045 patent/US20140349971A1/en not_active Abandoned
- 2014-10-31 JP JP2014222770A patent/JP5820045B2/ja not_active Expired - Lifetime
- 2014-12-18 NO NO2014031C patent/NO2014031I1/no not_active IP Right Cessation
- 2014-12-18 NO NO2014032C patent/NO2014032I1/no unknown
- 2014-12-18 NO NO2014030C patent/NO2014030I1/no unknown
2015
- 2015-06-19 US US14/744,501 patent/US20150283135A1/en not_active Abandoned
- 2015-07-20 HR HRP20150798TT patent/HRP20150798T4/hr unknown
- 2015-10-20 NL NL300781C patent/NL300781I1/nl unknown
- 2015-10-20 LU LU92853C patent/LU92853I2/xx unknown
- 2015-10-21 LU LU92854C patent/LU92854I2/xx unknown
- 2015-10-21 FR FR15C0072C patent/FR15C0072I2/fr active Active
- 2015-10-21 NL NL300768C patent/NL300768I2/nl unknown
- 2015-10-21 CY CY2015038C patent/CY2015038I2/el unknown
- 2015-10-21 LU LU92855C patent/LU92855I2/xx unknown
- 2015-10-21 CY CY2015039C patent/CY2015039I2/el unknown
- 2015-10-21 HU HUS1500053C patent/HUS1500053I1/hu unknown
- 2015-10-21 CY CY2015040C patent/CY2015040I2/el unknown
- 2015-10-21 FR FR15C0071C patent/FR15C0071I2/fr active Active
- 2015-10-21 FR FR15C0073C patent/FR15C0073I2/fr active Active
- 2015-10-21 BE BE2015C053C patent/BE2015C053I2/fr unknown
- 2015-10-21 HU HUS1500052C patent/HUS1500052I1/hu unknown
- 2015-10-21 HU HUS1500054C patent/HUS1500054I1/hu unknown
2016
- 2016-08-05 AU AU2016210733A patent/AU2016210733B2/en active Active
- 2016-12-19 US US15/383,076 patent/US20170100398A1/en not_active Abandoned
- 2016-12-20 LT LTPA2015035C patent/LTC1663240I2/lt unknown
- 2016-12-20 CY CY2016049C patent/CY2016049I2/el unknown
- 2016-12-20 HU HUS1600058C patent/HUS1600058I1/hu unknown
- 2016-12-20 FI FIEP04787096.9T patent/FI1663240T4/fi active
- 2016-12-20 FR FR16C1022C patent/FR16C1022I1/fr active Active
- 2016-12-20 FR FR16C1024C patent/FR16C1024I1/fr active Active
- 2016-12-20 NO NO2016025C patent/NO2016025I1/no unknown
- 2016-12-20 CY CY2016048C patent/CY2016048I2/el unknown
- 2016-12-20 NO NO2016026C patent/NO2016026I1/no unknown
- 2016-12-20 HU HUS1600059C patent/HUS1600059I1/hu unknown
- 2016-12-20 LT LTPA2016045C patent/LTPA2016045I1/lt unknown
2018
- 2018-04-11 US US15/950,548 patent/US20180228800A1/en not_active Abandoned
2019
- 2019-02-06 AU AU2019200813A patent/AU2019200813A1/en not_active Abandoned
- 2019-03-21 US US16/360,693 patent/US20190216807A1/en not_active Abandoned
2020
- 2020-02-07 US US16/784,404 patent/US20200171027A1/en not_active Abandoned
2021
- 2021-09-13 US US17/472,870 patent/US20220008417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AP2109A (en)	2010-02-26
NO2014031I1 (no)	2015-01-05
JP2015044839A (ja)	2015-03-12
CY2016048I1 (el)	2017-07-12
FR15C0071I2 (fr)	2016-02-12
CY2015039I1 (el)	2016-08-31
AU2016210733A1 (en)	2016-08-25
EP1663240A1 (en)	2006-06-07
NL300781I2 (hu)	2016-04-19
US20080200435A1 (en)	2008-08-21
FR15C0072I2 (fr)	2019-05-17
US20220008417A1 (en)	2022-01-13
US20150283135A1 (en)	2015-10-08
FR16C1024I1 (fr)	2017-02-03
NO20061374L (no)	2006-03-27
NO2014032I1 (no)	2015-01-05
HUS1500054I1 (hu)	2016-03-29
US20100029591A1 (en)	2010-02-04
JP5507791B2 (ja)	2014-05-28
AU2011201123A1 (en)	2011-04-07
NO2014030I1 (no)	2015-01-05
CY2015040I1 (el)	2016-08-31
NL300768I1 (hu)	2015-12-16
AU2004268390A1 (en)	2005-03-10
IL173438A0 (en)	2006-06-11
US20140349971A1 (en)	2014-11-27
US8841310B2 (en)	2014-09-23
NO2014030I2 (no)	2014-12-18
HK1092698A1 (en)	2007-02-16
AU2004268390B2 (en)	2011-03-31
CY2015038I1 (el)	2016-08-31
AU2011201123B2 (en)	2013-10-10
IL213104A0 (en)	2011-07-31
FI1663240T4 (fi)	2023-04-25
NO2016025I1 (hu)	2016-12-20
CA2537095A1 (en)	2005-03-10
NZ545306A (en)	2009-11-27
PL1663240T5 (pl)	2024-02-26
NL300768I2 (nl)	2023-08-09
AU2014203484B2 (en)	2016-09-29
HUS1500052I1 (hu)	2016-03-29
CY2015040I2 (el)	2016-08-31
CY2015039I2 (el)	2016-08-31
CA2537095C (en)	2012-05-29
IL173438A (en)	2012-03-29
IL213104A (en)	2016-02-29
MXPA06002437A (es)	2006-06-20
WO2005021001A1 (en)	2005-03-10
JP2007520443A (ja)	2007-07-26
JP5820045B2 (ja)	2015-11-24
CY2016049I1 (el)	2017-07-12
CY2015038I2 (el)	2016-08-31
FR15C0071I1 (hu)	2015-04-12
PL1663240T3 (pl)	2015-10-30
LTPA2016044I1 (lt)	2017-01-10
NL300781I1 (hu)	2016-04-19
EP1663240B1 (en)	2015-04-22
US20170100398A1 (en)	2017-04-13
MY169670A (en)	2019-05-08
US20200171027A1 (en)	2020-06-04
HRP20150798T4 (hr)	2023-06-09
KR20060090658A (ko)	2006-08-14
FR15C0073I1 (hu)	2015-04-12
HUS1500053I1 (hu)	2016-03-29
LTPA2016045I1 (lt)	2017-01-10
NO2014031I2 (no)	2014-12-18
AP2006003551A0 (en)	2006-04-30
LTC1663240I2 (lt)	2022-05-25
CY2016049I2 (el)	2017-07-12
US20190216807A1 (en)	2019-07-18
LU92855I2 (fr)	2015-12-21
US20180228800A1 (en)	2018-08-16
CY2016048I2 (el)	2017-07-12
CN101060844A (zh)	2007-10-24
HUS1600059I1 (hu)	2017-02-28
FR15C0073I2 (fr)	2016-02-12
BE2015C053I2 (hu)	2023-12-14
EP1663240B2 (en)	2023-03-01
CN101060844B (zh)	2012-01-04
FR16C1022I1 (fr)	2017-02-03
AU2014203484A1 (en)	2014-07-17
NO334877B1 (no)	2014-06-23
AU2019200813A1 (en)	2019-02-28
AU2016210733B2 (en)	2018-11-08
LU92853I2 (fr)	2015-12-21
FR15C0072I1 (hu)	2015-04-12
NO2016026I1 (no)	2016-12-20
NO2014032I2 (no)	2014-12-18
LU92854I2 (fr)	2015-12-21
HRP20150798T1 (hr)	2015-09-11
JP2012051915A (ja)	2012-03-15

Publication	Publication Date	Title
HUS1600059I1 (hu)	2017-02-28	Pirimidin-tartalmú NNRTI kombinációi RT inhibitorokkal
DK1562589T3 (da)	2009-02-16	Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
DK1730146T3 (da)	2011-08-15	Azaindoler anvendelige som inhibitorer af JAK og andre proteinkinaser
EP1704145A4 (en)	2009-08-05	SELECTIVE KINASEINHIBITORS
DK1940839T3 (da)	2013-10-14	Pyridopyrimidione Inhibitors of P13Ka
DK1611112T3 (da)	2012-11-19	Isoxazolforbindelser som hæmmere af varmechokproteiner
NO20045220L (no)	2005-01-19	Heterocykliske inhibitorer for kinaser
DK1532145T3 (da)	2007-01-15	Pyrazolpræparater der er anvendelige som inhibitorer af GSK-3
CY2013046I1 (el)	2015-11-04	Καινοτομος χρηση των αντισωματων αντι il-1bhta
DE602004008227D1 (de)	2007-09-27	Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase
DK1587542T3 (da)	2012-07-30	Anvendelse af anti-CD100-antistoffer
DE602005027308D1 (de)	2011-05-19	Stabile salze von olanzapin
EA201200891A1 (ru)	2013-01-30	Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
EP1697331A4 (en)	2010-08-04	INHIBITORS OF MITOTIC KINESINE
IS8399A (is)	2006-04-05	Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
ZA200700751B (en)	2008-08-27	Azalndoles useful as inhibitors of protein kinases
EP1697381A4 (en)	2009-03-11	INHIBITORS OF MITOTIC KINESINE
IS7963A (is)	2005-07-28	Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
ATE499348T1 (de)	2011-03-15	Stabiler polymorph von bifeprunoxmesilat
DK1663240T4 (da)	2023-04-17	Kombinationer af en pyrimidin-holdig nnrti med rt-inhibitorer
EP1954717A4 (en)	2009-07-08	PEPTIDE INHIBITORS OF ABL KINASE
DE112005000126D2 (de)	2006-11-30	Verwendungen von Glaskeramiken